Trial Profile
A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Hepatic fibrosis
- Focus Proof of concept; Therapeutic Use
- Acronyms POLT-HCV-SVR
- Sponsors Conatus Pharmaceuticals
- 08 Nov 2020 Results assessing safety and efficacy of emricasan in reducing or preventing progression of hepatic fibrosis in post-transplant HCV recipients achieving SVR with anti-viral therapy, and assess changes from baseline in ALT and caspases 3/7 published in the Liver Transplantation
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 02 Oct 2018 According to a Conatus Pharmaceuticals media release, data will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).